Clinical trials: Type 2 Diabetes Mellitus 1
Type 2 Diabetes Mellitus
4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes
This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants will receive an investigational product or placebo for 28 days.
- Trial name
- NCT03538743
- Testing
- PF-06882961
- Where
- 4 sites in United States
- Volunteers
- 98 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy
This project aims to develop high field MR techniques to detect nerve lesions in diabetic patients. The MRI findings will be compared to results from conventional evaluations and nerve conduction studies to determine the validity…
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy, Hereditary Axonal Neuropathy
- Trial name
- NCT01847937
- Where
- 5 sites in Denmark, Germany
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2
Diabetes Visual Function Supplement Study
This study will evaluate the effects of a novel multi-component dietary supplement on the visual function and retinal structure of patients with diabetes with both no diabetic retinopathy and mild to moderate diabetic…
- Conditions
- Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
- Trial name
- DiVFuSS (NCT01646047)
- Testing
- multi-component nutritional supplement capsules, multi-component dietary supplement
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- ZeaVision, LLC
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Diagnosis and Physiopathology of Insulin Allergy
Insulin allergy (IA) is still observed even with recombinant human insulin and insulin analogs. Obviously, the usual attitude facing an allergy, i. e.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Hypersensitivity, Immediate Hypersensitivity
- Trial name
- Allerdiab (NCT01407640)
- Testing
- Allergy tests
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function
This is an open-label study that will measure blood levels of different parts of a drug called GKS189075. People participating in this study will receive a single dose of 250mg GSK189075 by mouth.
- Conditions
- Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, Renal Insufficiency
- Trial name
- NCT00501462
- Testing
- GSK189075
- Where
- 4 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes Mellitus Maturity Onset
Smartguard Use in Real Life : a Longitudinal Study in Patients With Type 1 Diabetes
The reference treatment of the type 1 diabetes is intensified insulin therapy by insulin pump. The CGM (continuous glucose monitoring) is a technology available for a decade, which allows the continuous measure of interstitial…
- Trial name
- Smartguard (NCT03047486)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Caen
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring System
The purpose of this study is to evaluate the safety and effectiveness of the next-generation DexCom SEVEN Continuous Glucose Monitoring System (SEVEN.2 System) when worn for up to 7-days by subjects >18 years-old with diabetes…
- Trial name
- NCT00722241
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- DexCom, Inc.
Diabetes, Diabetes Mellitus, Type 1
Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes
This trial is conducted in Europe. The aim of this trial is to compare different ratios of explorative formulations, not similar to the proposed commercial formulation, of IDegAsp (co-formulation of insulin degludec/insulin…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01865305
- Testing
- insulin degludec/insulin aspart 30, insulin degludec/insulin aspart 40, insulin degludec/insulin aspart 50
- Where
- Germany
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Complications and Psychosocial Aspects of Diabetic Patients in Philippines
This study is conducted in Asia. The aim of this observational study is to describe the diabetes management, control status and complication profile in a diabetic population of Philippines.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare Asia (NCT00874159)
- Testing
- No treatment given
- Where
- Philippines
- Volunteers
- 770 people
- Sponsor
- Novo Nordisk A/S
Diabetes (Insulin-requiring, Type 1 or Type 2), Pancreatogenic Diabetes Mellitus
DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients
A Multicenter, Open label, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Electric Smart Insulin Pen DIA:CONN P8 in patients with Type 1, Type 2 or Pancreatogenic Diabetes Mellitus under Multiple Dose…
- Trial name
- NCT06406439
- Testing
- Smart Insulin Pen, Injection of bolus insulin via conventional therapy using insulin pen
- Where
- 9 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- G2e Co., Ltd
Diabetes Mellitus
A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition
To assess the impact of inhalation of insulin on glucose disposition in patients with type 1 diabetes
- Trial name
- NCT00287066
- Testing
- Inhaled Human Insulin, Regular Human Insulin
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
This trial is conducted in Europe, Oceania, and the United States of America (USA). The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin detemir (IDet) plus insulin aspart…
- Trial name
- BOOST™ (NCT00978627)
- Testing
- insulin degludec/insulin aspart, insulin detemir, insulin aspart
- Where
- 81 sites in United States, Australia and 8 more
- Volunteers
- 548 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
AI-Predicted Disease Trajectories in Diabetes: A Retrospective Study
The study explores the utilization of artificial intelligence (AI) to predict disease progression trajectories in patients with diabetes.
- Trial name
- AI-TRYDIA (NCT06280729)
- Testing
- AI-Analyis
- Where
- Italy
- Volunteers
- 10,000 people
- Sponsor
- IRCCS San Raffaele
Diabetes Mellitus, Type 2
Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.
This study will use scintigraphy techniques to measure gastric emptying rate of liquid and solid food at baseline and after administration of GSK716155 or placebo.
- Trial name
- NCT00537719
- Testing
- GSK716155
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in combination with a sulphonylurea in…
- Trial name
- NCT00602472
- Testing
- linagliptin
- Where
- 100 sites in Argentina, Belgium and 9 more
- Volunteers
- 1,058 people
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes Mellitus
Methylation of DNA in Children and Adolescents With Type 1 Diabetes Mellitus (METHYLDIAB)
Type 1 Diabetes Mellitus (T1DM) is a well-studied autoimmune disease resulting in insulin deficiency due to selective β-cell destruction.
- Trial name
- METHYLDIAB (NCT04139369)
- Where
- Greece
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Aristotle University Of Thessaloniki
Spinal Muscular Atrophy, Fragile X Syndrome
Early Check: Expanded Screening in Newborns
Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and…
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy
- Trial name
- NCT03655223
- Testing
- Confirmatory Testing
- Where
- United States
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- RTI International
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use
The purpose of this study is to demonstrate the performance of the Enlite Sensor over an entire calibration and wear period of 146 hours (6 days) when inserted in the abdomen and buttock and used with the Revel 2.0 Pumps in…
- Trial name
- NCT01464346
- Testing
- Enlite Sensor
- Where
- 7 sites in United States
- Volunteers
- 90 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 2
Phase III Study for Glimepiride + Metformin Hydrochloride (Amaryl M) Slow Release (SR)
Primary: To show the equivalence in terms of efficacy glycated hemoglobin (HbA1c) of glimepiride/metformin slow-release combination tablet (Amaryl M SR 2/500) once daily compared with fixed-dose glimepiride/metformin combination…
- Trial name
- NCT00437554
- Testing
- Glimepiride
- Where
- South Korea
- Volunteers
- 188 people
- Sponsor
- Handok Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.